Genexine, Inc.
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1999-06-08
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genexine.com
Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03144934
- Locations
- π°π·
Chungnam National University Hospital, Daejeon, Korea, Republic of
π°π·Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
π°π·Hallym University Medical Center-Kangnam, Seoul, Korea, Republic of
A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02946606
- Locations
- π°π·
Severance Hospital, Seoul, Korea, Republic of
Clinical Trial of GX-I7 in Healthy Volunteers
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02860715
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Biological: PlaceboBiological: GX-188E
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT02596243
- Locations
- πͺπͺ
East Tallinn Central Hospital, Tallinn, Estonia
πͺπͺNorth Estonia Medical Centre Foundation, Tallinn, Estonia
πͺπͺTartu University Hospital, Tartu, Estonia
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
- Conditions
- Cervical Intraepithelial Neoplasia 3
- Interventions
- Biological: GX-188E
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02411019
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Korea, Republic of
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02291991
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Biological: GX-188E
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02139267
- Locations
- π°π·
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
π°π·Cheil General Hospital & Women's Healthcare Center, Seoul, Korea, Republic of
π°π·The Catholic University of Korea Seoul St.Mary's Hospital, Seoul, Korea, Republic of
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
- Conditions
- Cervical Intraepithelial Neoplasia 3
- Interventions
- Biological: GX-188E
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02100085
- Locations
- π°π·
Cheil General Hospital & Women's Healthcare Center, Seoul, Korea, Korea, Republic of
Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: GX-051
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02079324
- Locations
- π°π·
Seoul St.Mary's Hospital of the Catholic University of Korea, Seoul, Korea, Republic of
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 257
- Registration Number
- NCT02044653
- Locations
- π°π·
Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of
π°π·Bundang Seoul National University College of Medicine, Gumi, Korea, Republic of
π°π·The Catholic University of Korea Incheon St.Mary's Hospital, Incheon, Korea, Republic of